Drugs / Flexyn2a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02388009 Comparator | Feb → May 2015 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 2 | NCT02646371 Comparator | Dec 2015 → Sep 2016 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flexyn2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02646371 ↗ |
| Modality | Vaccine | “Flexyn2a, a novel S. flexneri 2a bioconjugate vaccine” PMID 27581434 ↗ Dec 2016 |
| Route | Intramuscular | “injected intramuscularly” NCT02388009 ↗ |